BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25277787)

  • 1. Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma.
    Shin SY; Lee ST; Kim HJ; Kim SJ; Kim K; Kang ES; Kim SH
    J Clin Lab Anal; 2015 Nov; 29(6):505-10. PubMed ID: 25277787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
    Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis].
    Qiu Q; Zhu P; Wang MJ; Lu XZ; Dong YJ; Sun YH; Wang LH; Zhang Y; Bu DF; Wang WS; Liang ZY; Liu W; Qiu ZX; Ou JP; Cen XN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1071-8. PubMed ID: 27531777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging flow cytometric detection of del(17p) in bone marrow and circulating plasma cells in multiple myeloma.
    Mincherton TI; Lam SJ; Clarke SE; Hui HYL; Malherbe JAJ; Chuah HS; Sidiqi MH; Fuller KA; Erber WN
    Int J Lab Hematol; 2024 Jun; 46(3):495-502. PubMed ID: 38379463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
    Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
    Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
    Bacher U; Haferlach T; Kern W; Alpermann T; Schnittger S; Haferlach C
    Cancer Genet Cytogenet; 2010 Dec; 203(2):169-75. PubMed ID: 21156229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
    Rawstron AC; Orfao A; Beksac M; Bezdickova L; Brooimans RA; Bumbea H; Dalva K; Fuhler G; Gratama J; Hose D; Kovarova L; Lioznov M; Mateo G; Morilla R; Mylin AK; Omedé P; Pellat-Deceunynck C; Perez Andres M; Petrucci M; Ruggeri M; Rymkiewicz G; Schmitz A; Schreder M; Seynaeve C; Spacek M; de Tute RM; Van Valckenborgh E; Weston-Bell N; Owen RG; San Miguel JF; Sonneveld P; Johnsen HE;
    Haematologica; 2008 Mar; 93(3):431-8. PubMed ID: 18268286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic abnormalities and patterns of antigenic expression in multiple myeloma.
    Mateo G; Castellanos M; Rasillo A; Gutiérrez NC; Montalbán MA; Martín ML; Hernández JM; López-Berges MC; Montejano L; Bladé J; Mateos MV; Sureda A; de la Rubia J; Díaz-Mediavilla J; Pandiella A; Lahuerta JJ; Orfao A; San Miguel JF
    Clin Cancer Res; 2005 May; 11(10):3661-7. PubMed ID: 15897562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH.
    Dong H; Yang HS; Jagannath S; Stephenson CF; Brenholz P; Mazumder A; Chari A
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):366-74. PubMed ID: 22658896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Influence of CD117 Expression on Response of Multiple Myeloma Patients to Chemotherapy].
    Tang HL; Shu MM; Dong BX; Gu HT; Liang R; Bai QX; Yang L; Zhang T; Gao GX; Chen XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1346-51. PubMed ID: 26524035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma.
    Guo J; Su J; He Q; Li X; Zhao Y; Gu S; Fei C; Chang C
    Hematology; 2016 Apr; 21(3):152-61. PubMed ID: 25860485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
    Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
    Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of CD138 Immunomagnetic Bead Sorting Combined with Fluorescence in Situ Hybridization in Multiple Myeloma].
    Li QZ; Tan K; Liu YX; Huang H; Zhang Y; Chen HM; Chen ZZ; Zhu ZW; Yang BH; Hu GY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1496-1500. PubMed ID: 36208255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
    Mateo G; Montalbán MA; Vidriales MB; Lahuerta JJ; Mateos MV; Gutiérrez N; Rosiñol L; Montejano L; Bladé J; Martínez R; de la Rubia J; Diaz-Mediavilla J; Sureda A; Ribera JM; Ojanguren JM; de Arriba F; Palomera L; Terol MJ; Orfao A; San Miguel JF; ;
    J Clin Oncol; 2008 Jun; 26(16):2737-44. PubMed ID: 18443352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
    Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
    Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells.
    Jeong TD; Park CJ; Shim H; Jang S; Chi HS; Yoon DH; Kim DY; Lee JH; Lee JH; Suh C; Lee KH
    Korean J Hematol; 2012 Dec; 47(4):260-6. PubMed ID: 23320004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome microarray characterisation of chromosome arm 12p loss associated with complex molecular karyotype and recurrent adverse cytogenetic markers in multiple myeloma.
    Hung D; Lenton D; Eslick R; Blennerhassett R; Joshi M; McCaughan G; Day S; Wright D
    Genes Chromosomes Cancer; 2021 Oct; 60(10):668-677. PubMed ID: 34041820
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Hui H; Fuller KA; Eresta Jaya L; Konishi Y; Ng TF; Frodsham R; Speight G; Yamada K; Clarke SE; Erber WN
    J Clin Pathol; 2023 Nov; 76(11):763-769. PubMed ID: 36113967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
    An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
    Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
    Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.